Prescribing guide
Fabhalta (iptacopan)Vaccine requirements, REMS, C5 inhibitor switching, monitoring and prior authorization criteria for PNHFor prescribers and their offices treating paroxysmal nocturnal hemoglobinuria (PNH): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
REMS-certified prescriber, pneumococcal and meningococcal (ACWY and B) vaccination at least 2 weeks before day 1 or antibacterial prophylaxis with vaccines as soon as possible, no unresolved serious encapsulated bacterial infection, counseling with the Patient Guide and Patient Safety Card, and the pharmacy's documentation of vaccination status with the office.
Example PA threshold
FEP example: PNH, age 18 or older, documented baseline hemoglobin, vaccination including Hib, prescriber REMS enrollment, no dual therapy with another PA drug for PNH; 12 months, 400mg a day.
Monitoring
Serious infection with encapsulated bacteria at any time; hemolysis for at least 2 weeks after any discontinuation; serum lipids periodically; boosters on the ACIP schedule for a complement inhibitor.
Support line
Novartis Patient Support, 1-833-993-2242, Monday to Friday 8 AM to 8 PM Eastern, Co-Pay Plus as little as $0 for private insurance up to $20,000 a year plus $1,000 toward vaccines, Bridge Program free drug for up to 12 months, in-home vaccination; the label lists the same number for the REMS.
Give your patient their plan
A one-page handout for starting Fabhalta, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/fabhalta-paroxysmalBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Certify in the FABHALTA REMS | Review the Prescribing Information, the Healthcare Provider Safety Brochure, the Patient Guide and the Patient Safety Card, then submit the Prescriber Enrollment Form. There is no patient enrollment form. | FDA REMS page |
| Rule out active infection | Initiation is contraindicated with an unresolved serious infection caused by encapsulated bacteria, and the REMS requires the prescriber to assess for one before starting. Fabhalta is also contraindicated in serious hypersensitivity to iptacopan or any of the excipients. | FDA label |
| Vaccinate | Streptococcus pneumoniae and Neisseria meningitidis serogroups A, C, W, Y and B, at least 2 weeks before the first dose, on the ACIP complement inhibitor schedule, which differs from the vaccine prescribing information. The label says to revaccinate per ACIP considering the duration of therapy. | FDA label |
| Or prophylaxis | If treatment is urgent and the patient is not up to date, give antibacterial prophylaxis and the vaccines as soon as possible. The REMS requires the prescriber to provide the prophylaxis prescription. The label notes the optimal regimen and duration have not been studied. | FDA label |
| Counsel and hand over the card | Counsel with the Patient Guide and Patient Safety Card and give copies. The card is carried at all times during treatment and for 2 weeks after the last dose. | FDA REMS page |
| Plan the switch date | For a patient on eculizumab the first Fabhalta dose falls within 1 week of the last infusion, and for ravulizumab within 6 weeks, so the first fill has to arrive inside that window. | FDA label |
| Expect the pharmacy's call | The certified outpatient pharmacy obtains REMS authorization for every dispense and contacts the office to document vaccination status or the prophylaxis plan before the first fill. For patients not up to date at the start, it repeats that check before each dispense for up to 6 months. An inpatient pharmacy may dispense no more than a 30-day supply at discharge. | FDA REMS page |
| Novartis Patient Support and the PA | Enrollment gives the patient a dedicated team member, insurance support, Vaccination Support with in-home vaccination at no cost for eligible patients, and for private insurance free Fabhalta for up to 12 months while a prior authorization or appeal is pursued, if filed within the first 45 days of enrollment. | Novartis Patient Support |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, April 1, 2026. Approval twelve months at a time, renewed if hemoglobin has risen from the starting level with no unacceptable side effects, with a limit of 400mg a day. This policy was approved March 6, 2026 and cites the March 2025 label, so it predates the July 2026 label. That later change was to the IgA nephropathy use, not PNH. It still lists the Hib vaccine, which the FDA dropped from the label in March 2024. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis and age | PNH, age 18 or older | Diagnosis in the chart with the supporting test and date | FEP Blue policy |
| Baseline hemoglobin | A documented baseline hemoglobin; renewal requires an increase from the pretreatment baseline and no unacceptable toxicity | Hemoglobin with date, before the first dose and at renewal | FEP Blue policy |
| Vaccination | Streptococcus pneumoniae, Neisseria meningitidis and Hib at least 2 weeks before starting unless treatment cannot be delayed; the policy still lists Hib, which the label dropped in March 2024 | Vaccine names and dates, or the prophylaxis prescription | FEP Blue policy |
| REMS | Prescriber enrolled in the Fabhalta REMS, at approval and at renewal | Enrollment confirmation | FEP Blue policy |
| No dual therapy | Not used with another PNH drug requiring PA: eculizumab (Soliris), pegcetacoplan (Empaveli) or ravulizumab (Ultomiris) | Medication list with the date of the last C5 inhibitor dose | FEP Blue policy |
| Quantity and duration | Limit of 400mg per day, 12 months at a time | The label dose is 200mg twice daily | FEP Blue policy |
Fabhalta dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | Fabhalta 200mg orally twice daily, without regard to food; swallowed whole, never opened, broken or chewed. A 60-capsule bottle is a 30-day supply. | FDA label |
| From eculizumab | Start Fabhalta no later than 1 week after the last eculizumab dose. | FDA label |
| From ravulizumab | Start Fabhalta no later than 6 weeks after the last ravulizumab dose. | FDA label |
| From other PNH therapies | The label states there is no available information on the timeframe for starting Fabhalta after other PNH therapies. | FDA label |
| Missed dose | Take 1 dose as soon as possible, even if it is soon before the next scheduled dose, then resume the regular schedule. The label says to counsel PNH patients on adherence to minimize the risk of hemolysis. | FDA label |
| Stopping | Monitor closely for hemolysis for at least 2 weeks after the last dose. If discontinuation is necessary, consider alternative therapy; if hemolysis occurs, consider restarting Fabhalta or starting another PNH treatment. The Patient Safety Card is carried for 2 weeks after the last dose. | FDA label |
Monitoring the Fabhalta label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before day 1 | Vaccination status against the complement inhibitor schedule; unresolved serious encapsulated bacterial infection | Required by the label and REMS; vaccination is documented by the pharmacy with the office | FDA label |
| Any time | Serious infection: fever with or without chills, fever with rash, fever with chest pain and cough, dyspnea, tachypnea or tachycardia with fever, headache with fever, nausea, vomiting or stiff neck or back, confusion, flu-like myalgia, clammy skin, photophobia | Evaluate immediately and treat promptly; consider interrupting Fabhalta during treatment of a serious infection, weighing the risk of interruption in PNH | FDA label |
| After any discontinuation | Elevated LDH with a sudden fall in hemoglobin or PNH clone size, fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events, dysphagia, erectile dysfunction | Monitor at least 2 weeks after the last dose | FDA label |
| Periodically | Total cholesterol, LDL and triglycerides | Of 54 APPLY-PNH patients with normal baseline total cholesterol, 43% developed Grade 1 hypercholesterolemia; 2 of 102 patients across both PNH trials needed cholesterol-lowering medication. Start it if indicated. | FDA label |
| Platelets | Thrombocytopenia of any grade in 43% of 37 APPLY-PNH patients with normal baseline platelets | Three patients worsened to Grade 3 or higher. The label describes this under adverse reactions and sets no monitoring schedule. | FDA label |
| Response | Hemoglobin | In APPLY-PNH, 82.3% on Fabhalta against 0% on anti-C5 had a sustained rise of at least 2g/dL without transfusion at 24 weeks. In APPOINT-PNH, 77.5% of 40 complement inhibitor-naive patients did. | FDA label |
| Per ACIP | Boosters | Revaccinate on the ACIP schedule considering the duration of therapy; Novartis Patient Support helps patients track vaccinations and boosters | Novartis Patient Support |
| First weeks | Headache, diarrhea, abdominal pain, nausea | Rates were 19% against 3%, 15% against 6%, 15% against 3% and 10% against 3% in APPLY-PNH, Fabhalta against anti-C5 | FDA label |
Fabhalta drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Not recommended | Strong CYP2C8 inhibitors such as gemfibrozil, which may increase iptacopan exposure and the risk of adverse reactions | FDA label |
| Monitor response | CYP2C8 inducers such as rifampin may decrease iptacopan exposure; monitor clinical response and discontinue the inducer if loss of efficacy is evident | FDA label |
| Hepatic impairment | Not recommended in severe hepatic impairment (Child-Pugh class C); no dose adjustment in mild or moderate impairment | FDA label |
| Pregnancy and lactation | Data insufficient to identify a drug-associated risk; untreated PNH in pregnancy carries maternal and fetal risks, and use may be considered after a risk and benefit assessment. Breastfeeding should be discontinued during treatment and for 5 days after the final dose. | FDA label |
Why a first fill stalls, and the fix
- The pharmacy cannot document the vaccinesThe REMS requires the pharmacy to assess your vaccines or antibiotic plan with the prescriber before the first fill, and to document what it finds. Sending the vaccine dates, or the antibiotic prescription, gives the pharmacy what it needs.
- The prescription went to a pharmacy that is not certifiedOnly a limited number of pharmacies certified in the FABHALTA REMS dispense it. A prescription sent to a pharmacy outside the REMS is a routing problem, not a denial. The FABHALTA REMS website has a Certified Pharmacy Locator, and the office can resend it to a pharmacy on that list.
- Prior authorization pending or deniedThe FEP policy below asks for a baseline hemoglobin, proof of the vaccines, and the prescriber's REMS enrollment. For private insurance, the Novartis Bridge Program supplies Fabhalta free for up to 12 months while coverage is pursued. The prior authorization or an appeal must be filed within the first 45 days of enrollment.
- The plan does not allow 2 PNH drugs at onceThe FEP policy below rules out dual therapy with Soliris, Ultomiris or Empaveli. The Fabhalta label describes no overlap period, and it times the first dose from the last eculizumab or ravulizumab dose. The office can show the plan the date of that last dose.
- The vaccines themselves cost moneyCo-Pay Plus covers up to $1,000 a year of qualifying vaccine costs for people with private insurance, not counting administration fees. The Vaccination Support program gives the required shots at home at no cost for eligible patients, regardless of insurance.
- A copay you cannot payPrivate insurance: Co-Pay Plus, as little as $0, up to $20,000 a calendar year. Medicare, Medicaid, TRICARE, VA, DoD and other federal or state programs are excluded. Novartis points people without insurance, and some with government insurance, to the Novartis Patient Assistance Foundation at 1-800-277-2254. Our help paying page lists the charity funds that are open.
Novartis Patient Support
- One dedicated team member from the start, a Welcome Kit, and help locating and keeping track of vaccinations and boosters
- Co-Pay Plus for private insurance, as little as $0 for Fabhalta up to $20,000 a calendar year, plus up to $1,000 toward qualifying vaccine costs
- Co-Pay Plus is not valid under Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state health care program
- Bridge Program for private insurance: free Fabhalta for up to 12 months or until coverage is approved, if a prior authorization or appeal is filed within the first 45 days
- Vaccination Support: a licensed clinician gives the required vaccines at home at no cost for eligible patients, regardless of insurance
- Benefits verification, which Novartis says typically takes 2 to 3 business days, and help with insurance forms Novartis support FAQs
- Novartis Patient Assistance Foundation, 1-800-277-2254, for eligible people who are uninsured or have government insurance and cannot afford their costs
Questions prescribers' offices ask about Fabhalta
Which vaccines are required before Fabhalta?
Streptococcus pneumoniae and Neisseria meningitidis serogroups A, C, W, Y and B, at least 2 weeks before the first dose, on the ACIP schedule for complement inhibitor recipients, per the July 2026 label. The FDA removed the Hib vaccination recommendation from the label on March 26, 2024, though the boxed warning still names Hib among the organisms.
How do PNH patients switch from eculizumab or ravulizumab to Fabhalta?
Start Fabhalta no later than 1 week after the last eculizumab dose, or no later than 6 weeks after the last ravulizumab dose, per the July 2026 label. The label describes no overlap period. The label says no information is available on the timeframe for starting Fabhalta after other PNH therapies, which includes pegcetacoplan.
What does the Fabhalta REMS require?
A certified prescriber who assesses for unresolved serious encapsulated bacterial infection, checks and completes vaccination, writes antibacterial prophylaxis if treatment is urgent, and counsels with the Patient Guide and Patient Safety Card, per the REMS last updated July 16, 2026. There is no patient enrollment form. The certified pharmacy verifies prescriber certification for every dispense and documents vaccination status with the office. The label gives the REMS line as 1-833-993-2242 (1-833-99FABHA) and www.FABHALTA-REMS.com.
What monitoring does the Fabhalta label require in PNH?
At least 2 weeks of close monitoring for hemolysis after any discontinuation, per the July 2026 label, plus vigilance for serious encapsulated bacterial infection at any time and periodic serum lipids. The label also reports thrombocytopenia of any grade in 43% of 37 APPLY-PNH patients with normal baseline platelets.
What do insurers ask for to approve Fabhalta for PNH?
The FEP policy shown on this page, effective April 1, 2026, asks for age 18 or older, a documented baseline hemoglobin, vaccination including Hib at least 2 weeks before starting, prescriber REMS enrollment, and no dual therapy with Soliris, Ultomiris or Empaveli. It approves 12 months at 400mg a day, renewed on a hemoglobin increase from baseline.
Free email alert
Get an email when the Fabhalta label changes
One email the day the FDA revises the Fabhalta prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Fabhalta only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- FABHALTA (iptacopan) capsules, for oral use: prescribing information and Medication Guide, revised July 2026, Novartis, via openFDA and DailyMed, 2026-07-16.
- Approved Risk Evaluation and Mitigation Strategies (REMS): Fabhalta (iptacopan), NDA 218276, FDA, 2026-07-16.
- FABHALTA REMS, Novartis, 2026-11-13.
- About Novartis Patient Support | FABHALTA (iptacopan), Novartis, 2026-11-13.
- Novartis Patient Support FAQs | FABHALTA (iptacopan), Novartis, 2026-11-13.
- Vaccinations & Getting Started | PNH | FABHALTA (iptacopan), Novartis, 2026-11-13.
- Pharmacy Policy 5.85.055, Fabhalta (iptacopan), Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- NDA 218276/S-002 supplement approval letter, Hib vaccination recommendation removed, FDA, 2024-03-26.
- NDA 218276/S-007 supplement approval letter, Subpart H requirement fulfilled for IgA nephropathy, FDA, 2026-07-16.
- NDA 218276 approval letter, Fabhalta (iptacopan) capsules, FDA, 2023-12-05.
A reference drawn from the July 16, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 13, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.